Botulinum toxin in distony: experience in a thirdlevel hospital
DOI:
https://doi.org/10.28957/rcmfr.319Keywords:
Dystonia, Botulinum toxin type A, PainAbstract
Introduction. Dystonia is a movement disorder thatcauses functional impairments in thosewho suffer from it; the application of botulinum toxin is the treatment ofchoice due to its safety.
Objective. To describe the clinical outcomes of the long-term use of botulinum toxin in a group of patients with a diagnosis of dystonia treated in a hospital of third level ofcomplexityin Bogota, Colombia.
Methods. Observational study. The medical records of patients with a diagnosis of dystonia treated at the clinic of spasticity and dystonia of a health institution were reviewed. Pain was evaluated using the visual analog scale (VAS) and the perception of improvement in symptoms (recovery of the range of motion and reduction of involuntary movements); in addition, the specialist who applied the botulinum toxin analyzed the behavior of these variables overtime.
Results. 28 patients were included, the most frequent type of dystonia was cervical (75%) and the average time of treatment was 4.95 years (SD=2.89). It was found a reduction in pain of 79.32%, which was maintained over time (p<0.05); In addition, the perception of symptoms by the patient had an improvement of 83.75% (p<0.05) and the appreciation of results by the physiatrist was 88.39% (p=0.157).
Conclusions. Botulinum toxin proved to be a safe and effective treatment for the management of dystonia in the study population after severalcycles of application.
References
Skogseid IM. Dystonia new advances in classification, genetics, pathophysiology and treatment. Acta Neurol Scand Suppl. 2014;(198):13-9. Disponible en: https://doi.org/10.1111/ane.12231
Bhidayasiri R. Dystonia: genetics and treatment update. Neurologist. 2006;12(2):74-85. Disponible en: https://doi.org/10.1097/01.nrl.0000195831.46000.2d
Kutvonen O, Dastidar P, Nurmikko T. Pain in spasmodic torticollis. Pain. 1997;69(3):279-86. Disponible en: https://doi.org/10.1016/s0304-3959(96)03296-4
Konrad C, Vollmer-Haase J, Anneken K, Knecht S. Orthopedic and neurological complications of cervical dystonia—review of the literature. Acta Neurol Scand. 2004;109(6):369-73, Disponible en: https://doi.org/10.1111/j.1600-0404.2004.00281.x
Sławek J, Friedman A, Potulska A, Krystkowiak P, Gervais C, Banach M, et al. Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections. Funct Neurol. 2007;22(2):95-100
Friedman A, Fahn S. Spontaneous remissions in spasmodic torticollis. Neurology. 1986;36(3): 398-400. Disponible en: https://doi.org/10.1212/wnl.36.3.398
Mainka T, Erro R, Rothwell J, Kühn AA, Bhatia KP, Ganos C. Remission in dystonia - Systematic review of the literature and meta-analysis. Parkinsonism Relat Disord. 2019;66:9-15, Disponible en: https://doi.org/10.1016/j.parkreldis.2019.02.020
Albanese A, Asmus F, Bhatia KP, Elia AE, Elibol B, Filippini G, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol. 2011;18(1):5-18. Disponible en: https://doi.org/10.1111/j.1468-1331.2010.03042.x
Lungu C, Ahmad OF. Update on the Use of Botulinum Toxin Therapy for Focal and TaskSpecific Dystonias. Semin Neurol. 2016;36(1):41-6. Disponible en: https://doi.org/10.1055/s0035-1571211
Monnier G, Parratte B, Tatu L, Cosson A, Michel F, Metton G. EMG support in botulinum toxin treatment. Ann Readapt Med Phys. 2003;46(6):380-5. Disponible en: https://doi.org/10.1016/s0168-6054(03)00102-8
Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology. 2005;64(11):1949- 1951. Disponible en: https://doi.org/10.121201.WNL.0000163767.99354.C3
Comella CL, Jankovic J, Shannon KM, sui J, Swenson M, Leurgans S, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005;65(9):1423-9. Disponible en: https://doi.org/10.1212/01.wnl.0000183055.81056.5c
Pappert EJ, Germanson T. Botulinum toxin type B vs. type A in toxin-naive patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord. 2008;23(4):510-7. Disponible en: https://doi.org/10.1002/mds.21724
Dobryansky M, Korsh J, Shen AE, Aliano K. Botulinum toxin type A and B primary resistance. Aesthet Surg J. 2015;35(2):NP28-30. Disponible en: https://doi.org/10.1093/asj/sju027
Fabbri M, Leodori G, Fernandes RM, Bhidayasiri R, Marti MJ, Colosimo C, et al. Neutralizing Antibody and Botulinum Toxin Therapy: A Systematic Review and Meta-analysis. Neurotox Res. 2016;29(1):105-17. Disponible en: https://doi.org/10.1007/s12640-015-9565-5
Tyślerowicz M, Kiedrzyńska W, Adamkiewicz B, Jost WH, Sławek J.Cervical dystonia — improving the effectiveness of botulinum toxin therapy. Neurol Neurochir Pol. 2020;54(3):232- 42. Disponible en: https://doi.org/10.5603/PJNNS.a2020.002
Defazio G, Abbruzzese G, Livrea P, Berardelli A. Epidemiology of primary dystonia. Lancet Neurol. 2004;3(11):673-8. Disponible en: https://doi.org/10.1016/S1474-4422(04)00907-X
Solano-Atehortúa JM, Isaza-Jaramillo SP, Rendon-Bañol A, Buritica-Henao O. Prevalence of Dystonia in Antioquia, Colombia. Neuroepidemiology. 2016;46(2):137-43. Disponible en: https://doi.org/10.1159/000443834
Troung D, Brodsky M, Lew M, Brashear A, Jankovic J, Molho E, et al. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010;16(5):316-323. Disponible en: https://doi.org/10.1016/j.parkreldis.2010.03.002
Rodríguez FB, Duarte GS, Marques RE, Castelão M, Ferreira J, Sampaio C, et al. Tratamiento con toxina botulínica tipo A para personas con postura involuntaria de la cabeza, o distonía cervical. Cochrane Database of Systematic Reviews. 2020;11: CD003633. Disponible en: https://doi.org/10.1002/14651858.CD003633
Moreno-López CL. Diagnóstico y clasificación de la distonía. Acta Neurol Colomb. 2017;33(Suppl 1):S2-8
Simpson D, Hallet M, Ashman EJ, Comella CL, Green MW, Gronseth GS, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(9):1818-26. Disponible en: https://doi.org/10.1212/WNL.0000000000002560
Moreno-López CL, Cerquera-Cleves C. Toxina botulínica en el manejo de las distonías. Acta Neurol Colomb. 2017;33(Suppl 1):S32-37
Botox®. Ficha técnica. 2021 [citado marzo 24 de 2022]. Disponible en: http://www.allergan.com/assets/pdf/botox_pi.pdf
Xeomin®. Ficha técnica. 2015 [citado marzo 24 de 2022]. Disponible en: http://www.xeominaesthetic.com/wp-content/uploads/XEOMIN-Prescribing-Information.pdf
Dysport®. Ficha técnica. 2020 [citado marzo 24 de 2022]. Disponible en: https://www.drugs.com/pro/dysport.html
Castelão M, Marques RE, Duarte GS, Rodrigues FB, Ferreira J, Sampaio C, et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev. 2017;12(12):CD003633. Disponible en: https://doi.org/10.1002/14651858.CD003633.pub3
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Revista Colombiana de Medicina Física y Rehabilitación
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
